Coya Therapeutics, Inc.
COYA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001835022
No open-market purchases or sales by Coya Therapeutics, Inc. insiders were filed in the last 90 days; 54 institutions reported holding it in 13F filings for Q2 2026, worth $45.5M in total; Greenlight Capital is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 54
- 13F valueReported value at the end of Q2 2026
- $45.5M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding COYA, Q2 2026
1 superinvestor reports holding Coya Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
0.3%
Coya Therapeutics, Inc.'s share of the portfolio
- Shares
- 2,335,540
- Value
- $13.7M
Latest insider trades
Open-market purchases and sales by Coya Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 (view filing) | Nov 14 | Same day | Snyder David SChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +1.80K | $7.19 | +$12.9K | +25.7%8.80K after | |
| Nov 13, 2024 (view filing) | Nov 13 | Same day | Swaminathan ArunChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | $7.36 | +$36.8K | +100.0%10.0K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Grossman FredChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +2.71K | $7.37 | +$20.0K | New position2.71K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Swaminathan ArunChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | $7.34 | +$36.7K | New position5.00K after | |
| Mar 5, 2024 (view filing) | Aug 22, 2023 | 196 daysLate | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +1.00K | $3.62 | +$3.62K | +6.1%17.5K after | |
| Jan 4, 2023 (view filing)8:30 AM ET | Jan 3 | 1 day | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing)8:30 AM ET | Jan 3 | 1 day | Lee AnnDirector | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –9.48K after | Derivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Berman HowardChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | From original |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Berman HowardChief Executive Officer | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –5.00K after | From originalDerivative |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Hepner AdrianChief Medical Officer | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Coya Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 2,335,540 | $13.7M | 0.35% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 842,220 | $4.93M | 0.00% | −2,693−0.3% | Reduced |
| Alyeska Investment Group, L.P. | 800,000 | $4.68M | 0.01% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 631,912 | $3.70M | 0.33% | −343,492−35.2% | Reduced |
| CM Management, LLC | 400,000 | $2.34M | 1.49% | +25,000+6.7% | Added |
| Private Management Group Inc | 384,217 | $2.25M | 0.06% | +15,121+4.1% | Added |
| Marshall Wace, LLP | 249,793 | $1.46M | 0.00% | +24,001+10.6% | Added |
| Geode Capital Management, LLC | 228,243 | $1.34M | 0.00% | −5,159−2.2% | Reduced |
| Renaissance Technologies LLC | 192,986 | $1.13M | 0.00% | +89,022+85.6% | Added |
| Prosight Management, LP | 170,000 | $994.5K | 0.17% | −250,360−59.6% | Reduced |